+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Patient Age, Line of Treatment, Patient Type, End-User - Global Forecast 2026-2032- Product Image
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Patient Age, Line of Treatment, Patient Type, End-User - Global Forecast 2026-2032- Product Image
Sale

Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Patient Age, Line of Treatment, Patient Type, End-User - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968786
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Myeloma Drug Market is projected to reach USD 8.80 Billion in 2026. It is expected to continue growing at a CAGR of 7.29%, reaching USD 13.46 Billion by 2032.

Multiple myeloma is a plasma cell malignancy and remains one of the most treatment-intensive segments of hematologic oncology. The disease is characterized by recurrent relapse, clonal evolution, bone marrow involvement, immunosuppression, renal complications, anemia, and bone disease, creating sustained demand for effective multiple myeloma drugs across newly diagnosed, relapsed, and refractory settings.

The market is being reshaped by proteasome inhibitors, immunomodulatory agents, corticosteroid combinations, anti-CD38 monoclonal antibodies, selective nuclear export inhibitors, BCMA-targeted therapies, CAR-T cell therapies, bispecific antibodies, and emerging cereblon E3 ligase modulators. Clinical practice continues to move toward earlier use of combination regimens, measurable residual disease assessment, and personalized sequencing based on patient fitness, cytogenetic risk, prior exposure, and treatment response.

According to widely used oncology references and public health sources such as WHO/IARC GLOBOCAN, the American Cancer Society, NCCN, ESMO, FDA, and EMA, multiple myeloma incidence rises sharply with age and remains a major cause of hematologic cancer mortality despite substantial therapeutic advances. This creates a durable need for innovation that improves depth of response, prolongs progression-free survival, reduces treatment burden, and expands access to advanced therapies.

Transformative Shifts in the Multiple Myeloma Drug Landscape

The multiple myeloma drug landscape is undergoing a structural shift from traditional chemotherapy-centered care to multi-mechanism, immune-based, and biomarker-informed treatment strategies. Anti-CD38 antibodies have become foundational in many frontline and relapse regimens, while BCMA-directed CAR-T therapies and bispecific antibodies are redefining expectations in heavily pretreated relapsed or refractory multiple myeloma.

A second transformative shift is the movement of high-efficacy therapies into earlier lines of treatment. Regulatory decisions and clinical trial results increasingly support the use of quadruplet regimens, maintenance optimization, and risk-adapted approaches that aim to deepen response and extend remission. At the same time, clinicians must manage cumulative toxicities such as cytopenias, infections, neuropathy, thromboembolic risk, and cytokine release syndrome.

Commercial strategy is also changing. Manufacturers are investing in subcutaneous formulations, outpatient administration models, companion diagnostics, real-world evidence generation, and payer-facing value dossiers. As more mechanisms enter the market, competitive differentiation depends on survival outcomes, safety, convenience, manufacturability, access programs, and evidence in high-risk populations.

Cumulative Impact of Artificial Intelligence on Multiple Myeloma Drugs

Artificial intelligence is becoming an enabling layer across multiple myeloma drug discovery, development, diagnosis, and treatment optimization. In research, AI-supported target discovery, protein modeling, screening prioritization, and translational analytics are helping identify novel antigens, resistance pathways, and rational combination strategies. These tools are particularly relevant in a disease marked by genomic heterogeneity and treatment-induced clonal evolution.

In clinical development, AI can improve trial design by supporting patient stratification, site selection, eligibility matching, synthetic control exploration, and real-time safety monitoring. For multiple myeloma, where endpoints such as progression-free survival, overall survival, minimal residual disease negativity, and quality of life are central, advanced analytics can strengthen evidence generation when used with validated datasets and transparent governance.

In care delivery, AI-enabled decision support may help interpret laboratory trends, imaging, cytogenetics, sequencing history, and adverse event risk. However, adoption depends on clinical validation, interoperability, bias mitigation, data privacy, and regulatory oversight. The strongest near-term impact is expected where AI augments clinician decision-making rather than replacing specialist judgment.

Key Regional Insights Across the Multiple Myeloma Drug Market

North America remains a leading region for multiple myeloma drug innovation due to high oncology spending, rapid uptake of FDA-approved therapies, extensive clinical trial infrastructure, and strong specialist networks. The United States anchors regional demand through broad adoption of anti-CD38 antibodies, CAR-T therapy, bispecific antibodies, and evidence-based guidelines, while Canada emphasizes health technology assessment and publicly funded access pathways. Across the region, treatment standards are strongly influenced by regulatory review, guideline updates, transplant eligibility assessment, specialty pharmacy distribution, and real-world safety monitoring.

Europe is defined by EMA approvals, national reimbursement negotiations, and guideline-driven adoption across major markets. The European Union supports harmonized regulatory oversight, but access timelines vary by country, particularly for high-cost cell and gene therapies. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to specialized hematology centers, formal health technology assessment systems, and real-world evidence programs that evaluate clinical benefit, added therapeutic value, and budget impact.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India increase access to novel myeloma drugs, local clinical trials, and domestic biopharmaceutical development. China’s regulatory modernization and growing oncology infrastructure are improving availability of innovative therapies, while Japan’s aging population and advanced hematology practice support strong clinical demand. Latin America shows growing adoption in Brazil and Mexico but continues to face reimbursement, diagnostic capacity, and specialist access constraints. The Middle East, led by GCC health systems, is investing in oncology centers, medical tourism, and advanced therapeutics, while Africa remains underpenetrated due to limited specialist access, late diagnosis, constrained reimbursement, and uneven availability of advanced diagnostics.

Key Group Insights for Multiple Myeloma Drug Commercial Strategy

The G7 remains central to the multiple myeloma drug market because it includes major innovation, reimbursement, and clinical guideline economies such as the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. These countries shape global standards through regulatory decisions, pivotal trials, health technology assessments, transplant center networks, and adoption of advanced therapies including CAR-T cells and bispecific antibodies.

The European Union provides a structured regulatory and pharmacovigilance environment through EMA oversight, while individual member states determine pricing and reimbursement. This creates a market where clinical value must be matched with cost-effectiveness evidence, real-world outcomes, budget impact management, and equitable access strategies. NATO countries collectively include advanced healthcare systems with strong demand for secure pharmaceutical supply chains, resilient medicine access, and coordinated preparedness for critical therapies, including oncology biologics and cell therapies.

BRICS economies are increasingly important due to large patient populations, expanding cancer infrastructure, and growing domestic pharmaceutical capabilities in China, India, Brazil, Russia, and South Africa. China and India are particularly relevant for clinical development, manufacturing capacity, biosimilars, and broader access initiatives, while Brazil and South Africa highlight the need for public-sector affordability strategies. ASEAN markets are improving oncology access through public-private investment, regional procurement strategies, and expanding specialist care, although availability of premium biologics remains uneven across member countries. GCC countries are prioritizing specialty care modernization, advanced hospital infrastructure, international clinical collaborations, and access to innovative oncology drugs for high-complexity hematologic malignancies.

Key Country Insights in the Multiple Myeloma Drug Market

The United States is the most influential country market for multiple myeloma drugs because of rapid FDA approvals, high clinical trial activity, strong specialty pharmacy networks, advanced transplant and cellular therapy capacity, and early adoption of novel mechanisms. Canada follows a more centralized access model, with reimbursement decisions shaped by clinical benefit, cost-effectiveness, pan-Canadian review processes, and provincial implementation. Mexico and Brazil are important Latin American markets where demand is rising, but access depends on public coverage, private insurance, oncology center concentration, and availability of specialized hematology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major demand centers with established hematology networks and formal health technology assessment processes. Germany often provides comparatively early post-approval access within Europe, while France, Italy, and Spain emphasize negotiated reimbursement, evidence of added therapeutic value, and managed access considerations. The United Kingdom combines guideline-driven care with cost-effectiveness assessment and specialized cancer networks. Russia maintains domestic oncology demand but faces access variability linked to procurement dynamics, local availability, and geopolitical constraints.

In Asia-Pacific, China is expanding through domestic innovation, regulatory reform, broader oncology insurance coverage, and rising clinical trial participation. Japan remains a high-value market with advanced clinical practice, strong safety monitoring, and an aging population that increases the clinical relevance of tolerable long-term regimens. India has a substantial patient base and strong generics and biosimilars capabilities, though affordability remains a barrier for premium therapies and advanced cell-based treatment. Australia and South Korea show high standards of oncology care, reimbursement scrutiny, active clinical research ecosystems, and strong interest in innovative immune-based treatments for relapsed or refractory multiple myeloma.

Actionable Recommendations for Multiple Myeloma Drug Leaders

Industry leaders should prioritize differentiated clinical evidence that demonstrates meaningful improvements in progression-free survival, overall survival, minimal residual disease negativity, safety, convenience, and patient-reported outcomes. As the treatment landscape becomes crowded, products must show value in defined patient groups such as high-risk cytogenetics, frail older adults, renal impairment, prior anti-CD38 exposure, triple-class refractory disease, and patients requiring outpatient-friendly treatment options.

Organizations should invest in access strategies early, including health economic models, real-world evidence, outcomes-based contracting, and patient support programs. For advanced therapies, manufacturing reliability, vein-to-vein time, outpatient administration readiness, referral pathway development, infection prevention, and toxicity management protocols are critical competitive factors.

Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional distributors can accelerate trial execution and market penetration. Leaders should also strengthen pharmacovigilance, equitable access planning, supply chain resilience, and lifecycle management through new formulations, rational combinations, label expansion, and earlier-line indications.

Research Methodology for the Multiple Myeloma Drug Analysis

This executive summary is built using secondary research principles aligned with pharmaceutical market intelligence best practices. Sources considered include public regulatory databases, clinical guideline organizations, peer-reviewed oncology literature, cancer epidemiology resources, clinical trial registries, health technology assessment frameworks, and publicly available policy documents.

The analysis emphasizes verified and widely recognized evidence from organizations such as the FDA, EMA, WHO/IARC, NCCN, ESMO, national cancer agencies, and published clinical trial data. Market interpretation focuses on therapy class evolution, regional access dynamics, patient segmentation, regulatory activity, clinical development trends, and adoption drivers rather than unsupported numerical forecasting.

Insights were synthesized through triangulation of epidemiology, treatment guidelines, regulatory approvals, clinical development trends, reimbursement considerations, safety requirements, and care delivery constraints. The methodology favors data-backed interpretation, transparent assumptions, and practical relevance for pharmaceutical manufacturers, investors, payers, providers, and commercial strategy teams.

Conclusion: Future Outlook for Multiple Myeloma Drugs

The multiple myeloma drug market is advancing rapidly as immunotherapy, targeted therapy, and precision treatment strategies reshape standards of care. While the disease remains largely incurable for many patients, deeper responses and longer remission periods are increasingly achievable through combination regimens, maintenance strategies, measurable residual disease assessment, and novel immune-directed therapies.

Future success will depend on clinical differentiation, earlier-line expansion, access to advanced therapies, real-world outcomes, manufacturing readiness, and the ability to serve diverse patient populations across mature and emerging markets. Organizations that combine scientific innovation with evidence-based access planning, AI-enabled development, supply chain resilience, and patient-centered delivery models will be best positioned to lead the next phase of multiple myeloma treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Multiple Myeloma Drug Market, by Drug Class
7.1. Histone Deacetylase Inhibitors
7.2. Immunomodulatory Agents
7.2.1. Lenalidomide
7.2.2. Pomalidomide
7.2.3. Thalidomide
7.3. Monoclonal Antibodies
7.3.1. Daratumumab
7.3.2. Elotuzumab
7.3.3. Isatuximab
7.4. Proteasome Inhibitors
7.4.1. Bortezomib
7.4.2. Carfilzomib
7.4.3. Ixazomib
8. Multiple Myeloma Drug Market, by Line Of Therapy
8.1. First Line
8.2. Second Line
8.3. Third And Beyond
9. Multiple Myeloma Drug Market, by Treatment Regimen
9.1. Combination Therapy
9.1.1. Doublet Regimen
9.1.2. Quadruplet Regimen
9.1.3. Triplet Regimen
9.2. Monotherapy
10. Multiple Myeloma Drug Market, by Route Of Administration
10.1. Intravenous
10.2. Oral
10.3. Subcutaneous
11. Multiple Myeloma Drug Market, by Patient Age
11.1. Sixty And Above
11.2. Under Sixty
12. Multiple Myeloma Drug Market, by Line of Treatment
12.1. First-Line Therapy
12.2. Second-Line Therapy
12.3. Third-Line and Beyond
13. Multiple Myeloma Drug Market, by Patient Type
13.1. Newly Diagnosed Patients
13.2. Relapsed Patients
13.3. Refractory Patients
14. Multiple Myeloma Drug Market, by End-User
14.1. Hospitals
14.2. Specialty Clinics
14.3. Cancer Research Centers
15. Asia-Pacific Multiple Myeloma Drug Market
16. Europe Multiple Myeloma Drug Market
17. North America Multiple Myeloma Drug Market
18. Latin America Multiple Myeloma Drug Market
19. Africa Multiple Myeloma Drug Market
20. Middle East Multiple Myeloma Drug Market
21. NATO Multiple Myeloma Drug Market
22. G7 Multiple Myeloma Drug Market
23. BRICS Multiple Myeloma Drug Market
24. European Union Multiple Myeloma Drug Market
25. ASEAN Multiple Myeloma Drug Market
26. GCC Multiple Myeloma Drug Market
27. China Multiple Myeloma Drug Market
28. United States Multiple Myeloma Drug Market
29. Japan Multiple Myeloma Drug Market
30. India Multiple Myeloma Drug Market
31. Germany Multiple Myeloma Drug Market
32. United Kingdom Multiple Myeloma Drug Market
33. Australia Multiple Myeloma Drug Market
34. France Multiple Myeloma Drug Market
35. South Korea Multiple Myeloma Drug Market
36. Italy Multiple Myeloma Drug Market
37. Canada Multiple Myeloma Drug Market
38. Russia Multiple Myeloma Drug Market
39. Brazil Multiple Myeloma Drug Market
40. Mexico Multiple Myeloma Drug Market
41. Spain Multiple Myeloma Drug Market
42. Competitive Landscape
42.1. Market Concentration Analysis, 2025
42.1.1. Concentration Ratio (CR)
42.1.2. Herfindahl Hirschman Index (HHI)
42.2. Recent Developments & Impact Analysis, 2025
42.3. Product Portfolio Analysis, 2025
42.4. Benchmarking Analysis, 2025
43. Company Profiles
43.1. AbbVie Inc.
43.2. Adaptive Biotechnologies Corporation
43.3. Amgen Inc.
43.4. BeiGene, Ltd.
43.5. Bristol-Myers Squibb Company
43.6. Celgene Corporation
43.7. Cellectis S.A.
43.8. Daiichi Sankyo Company, Limited
43.9. Gilead Sciences, Inc.
43.10. GlaxoSmithKline plc
43.11. Ichnos Glenmark Innovation
43.12. Johnson & Johnson Services, Inc.
43.13. Karyopharm Therapeutics Inc.
43.14. Legend Biotech Corporation
43.15. Merck & Co., Inc.
43.16. MorphoSys AG
43.17. Novartis AG
43.18. Oncopeptides AB
43.19. Pfizer Inc.
43.20. PharmaMar, S.A.
43.21. Regeneron Pharmaceuticals, Inc.
43.22. Sanofi
43.23. Takeda Pharmaceutical Company Limited
43.24. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LENALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LENALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LENALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL POMALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL POMALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POMALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL THALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL THALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL THALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DARATUMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DARATUMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DARATUMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ELOTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ELOTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ELOTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ISATUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ISATUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ISATUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BORTEZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BORTEZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BORTEZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CARFILZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CARFILZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CARFILZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IXAZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IXAZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IXAZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL THIRD AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL THIRD AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL THIRD AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL UNDER SIXTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL UNDER SIXTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL UNDER SIXTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 134. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 138. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 141. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 145. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 173. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 174. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 177. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 179. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 180. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 181. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 183. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 184. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 185. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 199. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 200. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 201. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 202. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 203. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 204. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 205. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 206. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 207. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 209. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 210. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 211. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 212. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 214. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 215. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 216. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 218. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 219. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 220. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 222. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 223. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 224. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 225. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 226. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 227. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 228. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 229. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 230. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 231. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 232. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 233. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 235. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 236. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 237. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 251. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 252. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 254. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 255. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 257. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 258. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 259. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 261. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 262. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 264. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 265. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 267. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 268. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 269. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 270. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 271. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 272. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 274. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 275. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 276. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 277. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 280. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 281. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 282. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 283. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 284. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 285. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 287. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 288. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 289. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 303. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 305. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 306. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 307. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 308. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 309. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 310. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 311. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 312. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 313. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 314. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 315. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 316. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 318. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 319. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 320. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 321. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 322. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 323. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 324. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 325. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 326. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 327. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 328. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 329. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 330. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 331. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 332. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 333. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 334. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 335. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 336. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 337. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 338. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 339. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 340. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 341. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 349. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 350. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 351. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLIO

Companies Mentioned

The companies featured in this Multiple Myeloma Drug market report include:
  • AbbVie Inc.
  • Adaptive Biotechnologies Corporation
  • Amgen Inc.
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellectis S.A.
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ichnos Glenmark Innovation
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Oncopeptides AB
  • Pfizer Inc.
  • PharmaMar, S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.8 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.46 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Multiple Myeloma Therapeutics Market by Drug Class, Mode of Administration, Line of Therapy, Distribution Channel, End User - Global Forecast 2026-2032 - Product Image

Multiple Myeloma Therapeutics Market by Drug Class, Mode of Administration, Line of Therapy, Distribution Channel, End User - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2026-2034 - Product Image

Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2026 - Product Image

Multiple Myeloma Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Multiple Myeloma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Multiple Myeloma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 98 Pages
  • Global
From

About the Multiple Myeloma Drug Market

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.